Navigating Therapies, Challenges, and Recommendations for Treatment-Resistant Peripartum Depression: A Comprehensive Review
Abstract
1. Introduction
1.1. Associated Factors/Comorbidities
1.2. Diagnostics Obstacles
2. Methods
2.1. TRPD Current Therapeutics
2.2. Pharmacological Interventions
2.3. Augmentation Strategies
Category | Agent/Class | Mechanism of Action/Modality | Level of Evidence (TRD) | Level of Evidence (PPD) | Main Safety Warnings (Perinatal) | References |
---|---|---|---|---|---|---|
First-line Antidepressants | SSRIs (e.g., fluoxetine, sertraline) | Selective serotonin reuptake inhibition | Common first-line; often insufficient alone in TRD | Widely used; sertraline preferred in breastfeeding | Good safety profile; low infant exposure via breast milk | [26,27] |
SNRIs (e.g., venlafaxine, duloxetine) | Serotonin and norepinephrine reuptake inhibition | Used when SSRIs fail; moderate efficacy | Used cautiously postpartum | Venlafaxine frequently used postpartum; monitor for side effects | [26,27] | |
Bupropion | Dopamine–norepinephrine reuptake inhibition | Alternative option; especially for fatigue, anhedonia | Limited use in breastfeeding | Limited data in lactation; caution advised | [26] | |
Mirtazapine | Noradrenergic and specific serotonergic action | Often used as augmentation; sedation useful in insomnia | Limited safety data in lactation | Consider if insomnia or appetite loss dominate | [26] | |
Vortioxetine | Multimodal serotonergic activity | Modest efficacy in TRD; well tolerated | Not commonly used in PPD | Cognitive benefit in TRD | [26,27] | |
Agomelatine | Melatonergic agonist and 5-HT2C antagonist | Mild-moderate benefit in TRD | Limited data in PPD | Non-sedative; supports circadian rhythm | [26] | |
Second-line/Other Antidepressants | TCAs (e.g., amitriptyline) | Serotonin and norepinephrine reuptake inhibition | Used after SSRI/SNRI failure | Not typically used in PPD | Side effect burden, especially anticholinergic | [28] |
Quetiapine, trazodone | Multi-receptor activity | Used for augmentation; quetiapine has evidence in TRD | Not recommended in PPD due to sedation | Monitor metabolic and sedative side effects | [28] | |
Vilazodone, levomilnacipran | Serotonergic and norepinephrine/dopamine action | Considered after SSRI failure | Limited to no use in PPD | Novel agents, limited perinatal data | [28] | |
MAO Inhibitors | Phenelzine, tranylcypromine, etc. | Inhibit MAO-A/B, prevent monoamine breakdown | High efficacy in atypical/TRD | Contraindicated in pregnancy/lactation | Dietary restrictions and hypertensive crisis risk | [29] |
Neurosteroid | Brexanolone (IV allopregnanolone) | Positive allosteric modulator of GABA-A receptors | Not indicated for TRD | FDA-approved for PPD | Rapid action; 60-hour IV infusion required | [19] |
Zuranolone (zurzuvae) oral neurosteroid | positive allosteric modulator of GABA-A receptor) | Not indicated for TRD | FDA (2023) approved for PPD | Oral alternative to brexanolone’s IV infusion, with evidence for rapid, sustained symptom control from multiple RCTs. | [20] | |
NMDA Receptor Modulators | Esketamine (intranasal) | NMDA receptor antagonist; enhances glutamate signaling | FDA-approved for TRD; rapid effect | Not approved in pregnancy; possible postpartum use | In-clinic monitoring due to dissociation | [16] |
Ketamine (IV) | Non-selective NMDA receptor antagonist | Effective in 60–70% of TRD cases | Experimental use in severe PPD | Short-acting; some pilot postpartum trials | [18] | |
(2R,6R)-HNK | Ketamine metabolite; NMDA-independent | Promising early trials; non-dissociative | Not yet studied in PPD | Still investigational | [30] | |
Augmentation Strategies | Lithium, atypical antipsychotics | Enhance monoamine function; antipsychotic modulation | Effective as augmentation in TRD | Lithium not preferred during breastfeeding | Requires serum monitoring; side effect risk | [21] |
Immunomodulators | Infliximab, tocilizumab | Anti-cytokine (TNF-α, IL-6) inhibition | Promising in inflammation-related TRD | Not approved or studied in PPD | Off-label; biomarker-guided therapy | [17] |
Anti-inflammatory Agents | NSAIDs (e.g., celecoxib), cytokine blockers | Inhibit peripheral and CNS inflammation | Moderate benefit in inflamed TRD cases | Limited peripartum safety data | GI and cardiovascular risks; adjunctive only | [31] |
Psychedelic-Assisted Therapy | Psilocybin, MDMA | 5-HT2A receptor agonism, neuroplasticity facilitation | Rapid effects in trials for TRD | Not studied or approved for PPD | Requires psychotherapeutic setting | [32] |
Cannabinoids | CBD (cannabidiol) | Endocannabinoid modulation, serotonin activity | Preliminary TRD evidence | Insufficient safety data for PPD | Not FDA-approved; formulation challenges | [33] |
Novel Agents | Kappa opioid antagonists, sigma-1 modulators, etc. | Non-monoaminergic targets | Early-phase trials in TRD | No data in PPD | Potential future treatments | [34] |
Nutritional Adjuncts | Omega-3 fatty acids (EPA/DHA) | Anti-inflammatory; membrane fluidity; serotonin modulation | Safe adjunct in TRD | Safe during pregnancy and lactation | Modest efficacy; neurodevelopmental benefit in PPD | [35] |
2.4. Non-Pharmacological Interventions
Intervention | Modality/Mechanism | Evidence and Efficacy | Level of Evidence (TRD) | Level of Evidence (PPD) | Main Safety Warnings (Perinatal) | References |
---|---|---|---|---|---|---|
Cognitive Behavioral Therapy (CBT) (including CBTi) | Psychotherapy to restructure thoughts and behaviors; CBTi targets insomnia | Strong RCT/meta-analysis support; effective monotherapy or adjunct in TRD and PPD | Widely used and effective | Strong efficacy in pregnancy and postpartum | Safe during pregnancy/lactation; flexible delivery (teletherapy, group, individual) | [42,43] |
Mindfulness-Based Cognitive Therapy (MBCT) | Combines CBT with mindfulness to reduce rumination | Evidence supports relapse prevention in TRD | Effective in residual symptoms, relapse prevention | Limited data, but likely safe and beneficial | Gentle, non-invasive, supports emotional regulation | [44] |
Digital Therapeutics | App-based CBT and mood regulation tools | Growing evidence for mild/moderate TRD | Beneficial as adjunct or for access-limited patients | Under investigation for PPD | High accessibility; digital literacy dependent | [37] |
Virtual Reality Therapy | Immersive environments for therapeutic exposure | Emerging data in TRD, especially PTSD comorbidity | Promising in emotional regulation | Not yet studied in PPD | Costly and niche; not first-line | [38] |
Electroconvulsive Therapy (ECT) | Induces seizure via electrical stimulation | Gold standard in severe TRD (50–70% response) | Widely used in refractory TRD | Rarely used in PPD (case-based) | Not first-line in peripartum due to anesthesia/memory concerns | [36] |
Bifrontal ECT | Modified ECT with fewer cognitive side effects | Comparable efficacy to bilateral ECT | Considered safer cognitively in TRD | No data in PPD | Still requires anesthesia | [42] |
Repetitive Transcranial Magnetic Stimulation (rTMS) | Magnetic pulses stimulate dorsolateral prefrontal cortex | ~50% response in TRD; FDA-approved | Widely used in TRD | Demonstrated safety and efficacy in postpartum depression | Medication-free; non-invasive; safe during lactation | [45,46,47] |
Deep TMS (rdTMS) | Reaches deeper cortical and subcortical areas | Some evidence of superior efficacy in TRD | Effective in TRD | Not yet validated for PPD | High cost, limited availability | [48,49] |
tDCS (Transcranial Direct Current Stimulation) | Low current alters cortical excitability | 30–40% response in TRD | Used as low-cost, portable option | Limited data in PPD | Theoretical safety; not mainstream in perinatal settings | [50] |
Deep Brain Stimulation (DBS) | Implanted electrodes target deep brain regions | Up to 60% response in severe, refractory TRD | Experimental in advanced TRD | Not applicable in PPD | Invasive; contraindicated in pregnancy | [51] |
Neurofeedback | Brainwave training via real-time feedback | Promising early TRD studies | Potential for self-regulation support | No current data for PPD | Training-intensive; not routine | [52] |
Exercise/Physical Activity | Enhances BDNF, endorphins, circadian rhythm | Strong efficacy in mild-moderate depression; adjunct in TRD | Effective adjunct in TRD | Reduces PPD symptoms (SMD −0.41 to −0.53) | Safe, low-cost, improves physical/mental health | [53,54,55] |
Mind-Body Practices (e.g., Yoga) | Integrates movement, breathing, and mindfulness | Beneficial in both TRD and PPD | Used as adjunctive support | Particularly effective postpartum | Improves mood, sleep, and bonding | [56] |
Peer/Social Support and Psychoeducation | Group sessions, home visits, non-specialist support | Strong community-based evidence in PPD | Limited evidence in TRD; emerging in group therapy | Effective in reducing PPD, especially in low-resource settings | Safe, culturally adaptable, scalable | [57] |
Gene Therapy | Modifies gene expression via viral vectors | Preclinical success in TRD models | Experimental stage in TRD | No use in PPD | Ethical issues; not ready for clinical use | [58] |
Aspect | Pharmacological Interventions | Non-Pharmacological Interventions | |
---|---|---|---|
1. | Treatment Modalities and Mechanisms | TRD: Targets monoamine systems (serotonin, norepinephrine, dopamine), glutamate (e.g., ketamine), neurosteroids, inflammation. Often biochemical. PPD: Includes SSRIs, SNRIs, brexanolone, zuranolone (GABA-A modulator), with focus on safety in pregnancy/lactation. | TRD: Includes neuromodulation (ECT, TMS, DBS), psychotherapy (CBT, MBCT), and lifestyle/digital tools. Aims to restore neuroplasticity, cognition, emotional processing. PPD: Includes CBT/MBCT, rTMS, exercise, peer support, and digital therapies—non-invasive and safe for perinatal populations. |
2. | Efficacy and Evidence Base | TRD: Esketamine and ketamine offer rapid symptom relief. Antidepressants often need augmentation. MAOIs and glutamatergic agents show promise. Broad evidence base. PPD: SSRIs, brexanolone, and zuranolone supported by RCTs. Offers rapid onset but is complex to administer. Concerns about breastfeeding and fetal safety persist. | TRD: ECT and rTMS show robust short-term results; CBT/MBCT support long-term remission; digital tools are emerging. PPD: CBT and MBCT are highly effective; rTMS has growing support; exercise and peer-based support reduce symptoms and promote maternal-infant bonding. |
3. | Safety and Side Effects | TRD: Risk of sedation, metabolic and cardiovascular side effects; ketamine has misuse potential. Requires monitoring (e.g., lithium levels, MAOI diets). PPD: Risk of teratogenicity and neonatal effects; brexanolone requires 60-hour infusion under supervision. Breastfeeding exposure is a concern. | TRD: Side effects include cognitive effects (ECT), discomfort (TMS), but minimal systemic toxicity. PPD: Very safe—no systemic drug exposure. rTMS and CBT are well tolerated. Exercise low-risk when guided. No known adverse effects on fetus or infant. |
4. | Practical Considerations | TRD: Widely available agents; some novel treatments are expensive (e.g., esketamine). Pharmacogenomics in early use. PPD: SSRIs are first-line but patient hesitancy is common. Brexanolone is costly, IV-only, and underutilized. | TRD: Access limited by cost/availability (TMS, DBS); therapy requires time and engagement. Long-term cost-effective. PPD: Access challenges for TMS and therapy in some areas; digital and behavioral options increase scalability. High patient acceptance due to safety. |
2.5. Critical Appraisal
2.6. Challenges and Prospects
2.7. Recommendations for TRPD
3. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Sidhu, G.S.; Sidhu, T.K.; Kaur, P.; Lal, D.; Sangha, N.K. Evaluation of Peripartum Depression in Females. Int. J. Appl. Basic. Med. Res. 2019, 9, 201–205. [Google Scholar] [CrossRef]
- Gelaye, B.; Rondon, M.B.; Araya, R.; Williams, M.A. Epidemiology of maternal depression, risk factors, and child outcomes in low-income and middle-income countries. Lancet Psychiatry 2016, 3, 973–982. [Google Scholar] [CrossRef]
- Alzahrani, J.; Al-Ghamdi, S.; Aldossari, K.; Al-Ajmi, M.; Al-Ajmi, D.; Alanazi, F.; Aldossary, A.; Alharbi, A. Postpartum Depression Prevalence and Associated Factors: An Observational Study in Saudi Arabia. Medicina 2022, 58, 1595. [Google Scholar] [CrossRef]
- Guintivano, J.; Manuck, T.; Meltzer-Brody, S. Predictors of Postpartum Depression: A Comprehensive Review of the Last Decade of Evidence. Clin. Obstet. Gynecol. 2018, 61, 591–603. [Google Scholar] [CrossRef]
- Al Nasr, R.S.; Altharwi, K.; Derbah, M.S.; Gharibo, S.O.; Fallatah, S.A.; Alotaibi, S.G.; Almutairi, K.A.; Asdaq, S.M.B. Prevalence and predictors of postpartum depression in Riyadh, Saudi Arabia: A cross-sectional study. PLoS ONE 2020, 15, e0228666. [Google Scholar] [CrossRef]
- Yonkers, K.A.; Blackwell, K.A.; Glover, J.; Forray, A.; Stroud, L.R. Antidepressant use in pregnant and postpartum women. Annu. Rev. Clin. Psychol. 2014, 10, 369–392. [Google Scholar] [CrossRef]
- Prenoveau, J.M.; Craske, M.G.; West, V.; Giannakakis, A.; Zioga, M.; Lehtonen, A.; Davies, B.; Netsi, E.; Cardy, J.; Cooper, P.; et al. Maternal postnatal depression and anxiety and their association with child emotional negativity and behavior problems at two years. Dev. Psychol. 2017, 53, 50–62. [Google Scholar] [CrossRef]
- Murray, L.; Halligan, S.; Cooper, P. Effects of Postnatal Depression on Mother–Infant Interactions and Child Development. In The Wiley-Blackwell Handbook of Infant Development; Wiley: Hoboken, NJ, USA, 2010; pp. 192–220. [Google Scholar] [CrossRef]
- Stein, A.; Pearson, R.M.; Goodman, S.H.; Rapa, E.; Rahman, A.; McCallum, M.; Howard, L.M.; Pariante, C.M. Effects of perinatal mental disorders on the fetus and child. Lancet 2014, 384, 1800–1819. [Google Scholar] [CrossRef]
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed.; Psychiatric Publishing: Arlington, VA, USA, 2013. [Google Scholar]
- Biaggi, A.; Conroy, S.; Pawlby, S.; Pariante, C.M. Identifying the women at risk of antenatal anxiety and depression: A systematic review. J. Affect. Disord. 2016, 191, 62–77. [Google Scholar] [CrossRef]
- Wisner, K.L.; Sit, D.K.; McShea, M.C.; Rizzo, D.M.; Zoretich, R.A.; Hughes, C.L.; Eng, H.F.; Luther, J.F.; Wisniewski, S.R.; Costantino, M.L.; et al. Onset timing, thoughts of self-harm, and diagnoses in postpartum women with screen-positive depression findings. JAMA Psychiatry 2013, 70, 490–498. [Google Scholar] [CrossRef]
- Hill, K.E.; Cárdenas, E.F.; Yu, E.; Hammond, R.; Humphreys, K.L.; Kujawa, A. A systematic review of associations between hormone levels in hair and peripartum depression. Psychoneuroendocrinology 2025, 171, 107194. [Google Scholar] [CrossRef]
- Meltzer-Brody, S.; Howard, L.M.; Bergink, V.; Vigod, S.; Jones, I.; Munk-Olsen, T.; Honikman, S. Postpartum psychiatric disorders. Nat. Rev. Dis. Primers 2018, 4, 18022. [Google Scholar] [CrossRef]
- Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int. J. Surg. 2010, 8, 336–341. [Google Scholar] [CrossRef]
- Daly, E.J.; Trivedi, M.H.; Janik, A.; Li, H.; Zhang, Y.; Li, X.; Lane, R.; Lim, P.; Duca, A.R.; Hough, D.; et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients with Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry 2019, 76, 893–903. [Google Scholar] [CrossRef] [PubMed]
- Kappelmann, N.; Lewis, G.; Dantzer, R.; Jones, P.B.; Khandaker, G.M. Antidepressant activity of anti-cytokine treatment: A systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol. Psychiatry 2018, 23, 335–343. [Google Scholar] [CrossRef]
- Sanacora, G.; Frye, M.A.; McDonald, W.; Mathew, S.J.; Turner, M.S.; Schatzberg, A.F.; Summergrad, P.; Nemeroff, C.B.; American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry 2017, 74, 399–405. [Google Scholar] [CrossRef]
- Meltzer-Brody, S.; Colquhoun, H.; Riesenberg, R.; Epperson, C.N.; Deligiannidis, K.M.; Rubinow, D.R.; Li, H.; Sankoh, A.J.; Clemson, C.; Schacterle, A.; et al. Brexanolone injection in post-partum depression: Two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet 2018, 392, 1058–1070. [Google Scholar] [CrossRef]
- Fareed, A.; Vaid, R. FDA approval of Zurzuvae (zuranolone) to combat postpartum depression. Clin. Med. Insights Psychiatry 2023, 14, 11795573231208983. [Google Scholar] [CrossRef]
- Rafeyan, R.; Papakostas, G.I.; Jackson, W.C.; Trivedi, M.H. Inadequate Response to Treatment in Major Depressive Disorder: Augmentation and Adjunctive Strategies. J. Clin. Psychiatry 2020, 81, OT19037BR3. [Google Scholar] [CrossRef] [PubMed]
- Nierenberg, A.A.; Fava, M.; Trivedi, M.H.; Wisniewski, S.R.; Thase, M.E.; McGrath, P.J.; Alpert, J.E.; Warden, D.; Luther, J.F.; Niederehe, G.; et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: A STAR*D report. Am. J. Psychiatry 2006, 163, 1519–1530. [Google Scholar] [CrossRef] [PubMed]
- Spielmans, G.I.; Berman, M.I.; Linardatos, E. Adjunctive atypical antipsychotic treatment for major depressive disorder: A meta-analysis of depression, quality of life, and safety outcomes. PLoS Med. 2013, 10, e1001403. [Google Scholar] [CrossRef]
- Voineskos, D.; Daskalakis, Z.J.; Blumberger, D.M. Management of Treatment-Resistant Depression: Challenges and Strategies. Neuropsychiatry Dis Treat. 2020, 16, 221–234. [Google Scholar] [CrossRef]
- Kennedy, S.H.; Lam, R.W.; McIntyre, R.S.; Tourjman, S.V.; Bhat, V.; Blier, P.; Hasnain, M.; Jollant, F.; Levitt, A.J.; MacQueen, G.M.; et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. Can J. Psychiatry 2016, 61, 540–560. [Google Scholar] [CrossRef] [PubMed]
- De Crescenzo, F.; Perelli, F.; Armando, M.; Vicari, S. Selective serotonin reuptake inhibitors (SSRIs) for postpartum depression (PPD): A systematic review of randomized clinical trials. J. Affect. Disorder. 2014, 152–154, 39–44. [Google Scholar] [CrossRef]
- Dimcea, D.A.; Petca, R.C.; Dumitrașcu, M.C.; Șandru, F.; Mehedințu, C.; Petca, A. Postpartum Depression: Etiology, Treatment, and Consequences for Maternal Care. Diagnostics 2024, 14, 865. [Google Scholar] [CrossRef]
- Daly, E.J.; Singh, J.B.; Fedgchin, M.; Cooper, K.; Lim, P.; Shelton, R.C.; Thase, M.E.; Winokur, A.; Van Nueten, L.; Manji, H.; et al. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry 2018, 75, 139–148. [Google Scholar] [CrossRef]
- Thomas, S.J.; Shin, M.; McInnis, M.G.; Bostwick, J.R. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: Strategies for the management of treatment- resistant depression. Pharmacotherapy 2015, 35, 433–449. [Google Scholar] [CrossRef] [PubMed]
- Zanos, P.; Moaddel, R.; Morris, P.J.; Georgiou, P.; Fischell, J.; Elmer, G.I.; Alkondon, M.; Yuan, P.; Pribut, H.J.; Singh, N.S.; et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 2016, 533, 481–486. [Google Scholar] [CrossRef] [PubMed]
- Raison, C.L.; Rutherford, R.E.; Woolwine, B.J.; Shuo, C.; Schettler, P.; Drake, D.F.; Haroon, E.; Miller, A.H. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers. JAMA Psychiatry 2013, 70, 31–41. [Google Scholar] [CrossRef]
- Carhart-Harris, R.L.; Goodwin, G.M. The therapeutic potential of psychedelic drugs: Past, present, and future. Neuropsychopharmacology 2017, 42, 2105–2113. [Google Scholar] [CrossRef]
- Blessing, E.M.; Steenkamp, M.M.; Manzanares, J.; Marmar, C.R. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics 2015, 12, 825–836. [Google Scholar] [CrossRef]
- Elias, E.; Zhang, A.Y.; Manners, M.T. Novel Pharmacological Approaches to the Treatment of Depression. Life 2022, 12, 196. [Google Scholar] [CrossRef]
- Mischoulon, D.; Nierenberg, A.A.; Schettler, P.J.; Kinkead, B.L.; Fehling, K.; Martinson, M.A.; Hyman Rapaport, M. A double-blind, randomized controlled clinical trial comparing eicosapentaenoic acid versus docosahexaenoic acid for depression. J. Clin. Psychiatry 2015, 76, 54–61. [Google Scholar] [CrossRef]
- Lupi, M.; Martinotti, G.; Santacroce, R.; Cinosi, E.; Carlucci, M.; Marini, S.; Acciavatti, T.; di Giannantonio, M. Transcranial Direct Current Stimulation in Substance Use Disorders: A Systematic Review of Scientific Literature. J. ECT 2017, 33, 203–209. [Google Scholar] [CrossRef]
- Mantani, A.; Kato, T.; Furukawa, T.A.; Horikoshi, M.; Imai, H.; Hiroe, T.; Chino, B.; Funayama, T.; Yonemo, N.; Zhou, Q.; et al. Correction: Smartphone Cognitive Behavioral Therapy as an Adjunct to Pharmacotherapy for Refractory Depression: Randomized Controlled Trial. J. Med. Internet Res. 2018, 20, e11702. [Google Scholar] [CrossRef]
- Mills, J.C.; Harman, J.S.; Cook, R.L.; Marlow, N.M.; Harle, C.A.; Duncan, R.P.; Bengtson, A.M.; Penc, B.W. Comparative effectiveness of dual-action versus single-action antidepressants for the treatment of depression in people living with HIV/AIDS. J. Affect. Disord. 2017, 215, 179–186. [Google Scholar] [CrossRef]
- Lisanby, S.H.; Husain, M.M.; Rosenquist, P.B.; Maixner, D.; Gutierrez, R.; Krystal, A.; Gilmer, W.; Marangell, L.B.; Aaronson, S.; Daskalakis, Z.J.; et al. Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: Clinical predictors of outcome in a multisite, randomized controlled clinical trial. Neuropsychopharmacology 2009, 34, 522–534. [Google Scholar] [CrossRef] [PubMed]
- Dennis, C.L.; Falah-Hassani, K.; Shiri, R.; Prevalence, Risk Factors, and Treatment Outcomes Study of Depression during Pregnancy Team. Prevalence of antenatal and postnatal anxiety: Systematic review and meta-analysis. Br. J. Psychiatry 2017, 210, 315–323. [Google Scholar] [CrossRef] [PubMed]
- Daley, A.J.; Foster, L.; Long, G.; Palmer, C.; Robinson, O.; Walmsley, H.; Ward, R. The effectiveness of exercise for preventing and treating antenatal depression: A systematic review with meta-analysis. BJOG Int. J. Obstet. Gynaecol. 2015, 122, 57–62. [Google Scholar] [CrossRef]
- Holtzheimer, P.E.; Husain, M.M.; Lisanby, S.H.; Taylor, S.F.; Whitworth, L.A.; McClintock, S.; Slavin, K.V.; Berman, J.; McKhann, G.M.; Patil, P.G.; et al. Subcallosal cingulate deep brain stimulation for treatment-resistant depression: A multisite, randomized, sham-controlled trial. Lancet Psychiatry 2012, 1, 548–557. [Google Scholar] [CrossRef] [PubMed]
- Li, X.; Laplante, D.P.; Paquin, V.; Lafortune, S.; Elgbeili, G.; King, S. Effectiveness of cognitive behavioral therapy for perinatal maternal depression, anxiety and stress: A systematic review and meta-analysis of randomized controlled trials. Clin. Psychol. Rev. 2022, 92, 102129. [Google Scholar] [CrossRef]
- McGirr, A.; Van den Eynde, F.; Tovar-Perdomo, S.; Fleck, M.P.; Berlim, M.T. Effectiveness and acceptability of accelerated repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant major depressive disorder: An open-label trial. J. Affect. Disord. 2015, 173, 216–220. [Google Scholar] [CrossRef]
- Sitaram, R.; Ros, T.; Stoeckel, L.; Haller, S.; Scharnowski, F.; Lewis-Peacock, J.; Weiskopf, N.; Blefari, M.L.; Rana, M.; Oblak, E.; et al. Author Correction: Closed-loop brain training: The science of neurofeedback. Nat. Rev. Neurosci. 2019, 20, 314. [Google Scholar] [CrossRef] [PubMed]
- Liu, C.; Pan, W.; Jia, L.; Li, L.; Zhang, X.; Ren, Y.; Ma, X. Efficacy and safety of repetitive transcranial magnetic stimulation for peripartum depression: A meta-analysis of randomized controlled trials. Psychiatry Res. 2020, 294, 113543. [Google Scholar] [CrossRef] [PubMed]
- Cox, E.Q.; Killenberg, S.; Frische, R.; McClure, R.; Hill, M.; Jenson, J.; Pearson, B.; Meltzer- Brody, S.E. Repetitive transcranial magnetic stimulation for the treatment of postpartum depression. J. Affect. Disord. 2020, 264, 193–200. [Google Scholar] [CrossRef]
- Brunoni, A.R.; Moffa, A.H.; Sampaio-Junior, B.; Borrione, L.; Moreno, M.L.; Fernandes, R.A.; Fregni, F. Trial of electrical direct-current therapy versus escitalopram for depression. N. Engl. J. Med. 2017, 376, 2523–2533. [Google Scholar] [CrossRef] [PubMed]
- Lee, H.J.; Kim, S.M.; Kwon, J.Y. Repetitive transcranial magnetic stimulation treatment for peripartum depression: Systematic review & meta-analysis. BMC Pregnancy Childbirth 2021, 21, 118. [Google Scholar] [CrossRef]
- Trifu, S.; Sevcenco, A.; Stănescu, M.; Drăgoi, A.M.; Cristea, M.B. Efficacy of electroconvulsive therapy as a potential first-choice treatment in treatment-resistant depression (Review). Exp. Ther. Med. 2021, 22, 1281. [Google Scholar] [CrossRef]
- Strauss, C.; Cavanagh, K.; Oliver, A.; Pettman, D.; Hayward, M. Mindfulness-based interventions for people diagnosed with a current episode of anxiety or depressive disorder: A meta- analysis of randomized controlled trials. PLoS ONE 2014, 9, e96110. [Google Scholar] [CrossRef]
- Coppola, G.; Cortese, F.; Bracaglia, M.; Di Lorenzo, C.; Serrao, M.; Magis, D.; Pierelli, F. The function of the lateral inhibitory mechanisms in the somatosensory cortex is normal in patients with chronic migraine. Clin. Neurophysiol. 2020, 131, 880–886. [Google Scholar] [CrossRef]
- Shirayama, Y.; Chaki, S. Neurochemistry of the nucleus accumbens and its relevance to depression and antidepressant action in rodents. Curr. Neuropharmacol. 2006, 4, 277–291. [Google Scholar] [CrossRef] [PubMed]
- Poyatos-León, R.; García-Hermoso, A.; Sanabria-Martínez, G.; Álvarez-Bueno, C.; Cavero- Redondo, I.; Martínez-Vizcaíno, V. Effects of exercise-based interventions on postpartum depression: A meta-analysis of randomized controlled trials. Birth 2017, 44, 200–208. [Google Scholar] [CrossRef] [PubMed]
- Marconcin, P.; Peralta, M.; Gouveia, É.R.; Ferrari, G.; Carraça, E.; Ihle, A.; Marques, A. Effects of Exercise during Pregnancy on Postpartum Depression: A Systematic Review of Meta-Analyses. Biology 2021, 10, 1331. [Google Scholar] [CrossRef]
- Schuch, F.B.; Vancampfort, D.; Rosenbaum, S.; Richards, J.; Ward, P.B.; Stubbs, B. Exercise improves physical and psychological outcomes in people with depression: A meta-analysis including the evaluation of control group response. Psychiatry Res. 2016, 241, 47–54. [Google Scholar] [CrossRef]
- Sockol, L.E.; Epperson, C.N.; Barber, J.P. A meta-analysis of treatments for perinatal depression. Clin. Psychol. Rev. 2011, 31, 839–849. [Google Scholar] [CrossRef]
- DeRubeis, R.J.; Hollon, S.D.; Amsterdam, J.D.; Shelton, R.C.; Young, P.R.; Salomon, R.M.; O’Reardon, J.P.; Lovett, M.L.; Gladis, M.M.; Brown, L.L.; et al. Cognitive therapy vs. medications in the treatment of moderate to severe depression. Arch. Gen. Psychiatry 2005, 62, 409–416. [Google Scholar] [CrossRef]
- Stewart, D.E.; Vigod, S.N. Postpartum Depression: Pathophysiology, Treatment, and Emerging Therapeutics. Annu. Rev. Med. 2019, 70, 183–196. [Google Scholar] [CrossRef]
- Yonkers, K.A.; Wisner, K.L.; Stewart, D.E.; Oberlander, T.F.; Dell, D.L.; Stotland, N.; Ramin, S.; Chaudron, L.; Lockwood, C. The management of depression during pregnancy: A report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen. Hosp. Psychiatry 2009, 31, 403–413. [Google Scholar] [CrossRef]
- Peng, L.; Fu, C.; Xiong, F.; Zhang, Q.; Liang, Z.; Chen, L.; He, C.; Wei, Q. Effects of repetitive transcranial magnetic stimulation on depression symptoms and cognitive function in treating patients with postpartum depression: A systematic review and meta-analysis of randomized controlled trials. Psychiatry Res. 2020, 290, 113124. [Google Scholar] [CrossRef]
- Silang, K.; MacKinnon, A.; Madsen, J.; Giesbrecht, G.F.; Campbell, T.; Keys, E.; Freeman, M.; Dewsnap, K.; Jung, J.W.; Tomfohr-Madsen, L.M. Sleeping for two: A randomized controlled trial of cognitive behavioural therapy for insomnia (CBT I) delivered in pregnancy and secondary impacts on symptoms of postpartum depression. J. Affect. Disord. 2024, 362, 670–678. [Google Scholar] [CrossRef] [PubMed]
- Daley, A.; Jolly, K.; MacArthur, C. The effectiveness of exercise in the management of post-natal depression: Systematic review and meta-analysis. Fam. Pract. 2009, 26, 154–162. [Google Scholar] [CrossRef] [PubMed]
- Liu, L.; Liu, C.; Liu, X.; Yang, Y. Summary of the effect of an exercise intervention on antenatal depression and the optimal program: A systematic review and Meta-analysis. BMC Pregnancy Childbirth 2023, 23, 293. [Google Scholar] [CrossRef] [PubMed]
- Saharoy, R.; Potdukhe, A.; Wanjari, M.; Taksande, A.B. Postpartum Depression and Maternal Care: Exploring the Complex Effects on Mothers and Infants. Cureus 2023, 15, e41381. [Google Scholar] [CrossRef]
- O’Hara, M.W.; Wisner, K.L. Perinatal mental illness: Definition, description and aetiology. Best. Pract. Res. Clin. Obstet. Gynaecol. 2014, 28, 3–12. [Google Scholar] [CrossRef]
- Mouliou, D.S. C-Reactive Protein: Pathophysiology, Diagnosis, False Test Results and a Novel Diagnostic Algorithm for Clinicians. Diseases 2023, 11, 132. [Google Scholar] [CrossRef]
- Howard, L.M.; Khalifeh, H. Perinatal mental health: A review of progress and challenges. World Psychiatry 2020, 19, 313–327. [Google Scholar] [CrossRef]
- Milgrom, J.; Garner, B.; Rodrigues, A.; Fisher, J.; Borninkhof, J.; Kavanagh, D.; Gemmill, A.W. National Implementation of Perinatal Mental Health Treatment—The MumSpace Digital Stepped-Care Model. Int. J. Environ. Res. Public Health 2025, 22, 361. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Wasti, A.Z.; Almutairi, S.; Huq, M.; Hussain, A.; Mackawy, A.M.H.; Jabeen, F.; Alharbi, B.; Memon, A.G.; Ahmed, M. Navigating Therapies, Challenges, and Recommendations for Treatment-Resistant Peripartum Depression: A Comprehensive Review. Healthcare 2025, 13, 2426. https://doi.org/10.3390/healthcare13192426
Wasti AZ, Almutairi S, Huq M, Hussain A, Mackawy AMH, Jabeen F, Alharbi B, Memon AG, Ahmed M. Navigating Therapies, Challenges, and Recommendations for Treatment-Resistant Peripartum Depression: A Comprehensive Review. Healthcare. 2025; 13(19):2426. https://doi.org/10.3390/healthcare13192426
Chicago/Turabian StyleWasti, Afshan Zeeshan, Sarah Almutairi, Mohsina Huq, Amal Hussain, Amal Mohamad Husein Mackawy, Farah Jabeen, Basmah Alharbi, Anjuman Gul Memon, and Mawahib Ahmed. 2025. "Navigating Therapies, Challenges, and Recommendations for Treatment-Resistant Peripartum Depression: A Comprehensive Review" Healthcare 13, no. 19: 2426. https://doi.org/10.3390/healthcare13192426
APA StyleWasti, A. Z., Almutairi, S., Huq, M., Hussain, A., Mackawy, A. M. H., Jabeen, F., Alharbi, B., Memon, A. G., & Ahmed, M. (2025). Navigating Therapies, Challenges, and Recommendations for Treatment-Resistant Peripartum Depression: A Comprehensive Review. Healthcare, 13(19), 2426. https://doi.org/10.3390/healthcare13192426